A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 420 participants.
Also called NCT07642050
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 420 participants
- Sponsor
- Biohaven Therapeutics Ltd.
- Registry
-
NCT07642050
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07642050. Randomized; quadruple masking; primary purpose treatment. Start 2026-06 (anticipated); primary completion 2028-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
- Condition
- IgA Nephropathy
- Intervention (Drug)
- BHV-1400
- Intervention (Drug)
- Placebo
- Lead sponsor
- Biohaven Therapeutics Ltd.
Record details
- Record id
cardio:ct-nct07642050- Content hash
187f55e9e2af023f88b585ca317b8ffc4cdea7f3d52f2caa40fa291fd5c7c545